SQZ Biotechnologies is a clinical stage cell therapy company developing innovative treatments for multiple therapeutic areas.
SQZ currently focuses on the development of novel treatments that leverage targeted immune modulation to impact oncology and autoimmune diseases.
SQZ Biotechnologies was founded in 2013 by Armon Sharei. The company is headquartered in Watertown, Massachusetts.
SQZ Biotechnologies utilizes the proprietary CellSqueeze® platform to develop a new generation of cell therapies. Cell Squeeze®, physically squeezes cells through a microfluidic constriction to temporarily disrupt the cell membrane, allowing desired cargo to diffuse into the cell cytosol before the membrane reseals.
SQZ is developing an additional novel cell therapy platform in oncology, activating antigen carriers (SQZ AACs), as well as continuing to develop its earlier stage platform, tolerizing antigen carriers (SQZ TACs), for autoimmune diseases and tolerance applications.
SQZ Biotechnologies is backed by GV, Temasek, Illumina Ventures, Invus, JDRF T1D Fund, NanoDimension, Polaris Partners and others. The company raised $65M in a Series D round on May 18, 2020. This brings SQZ's total funding to $173.7M to date.